Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hpv oncopredict

HPV OncoPredict SIGNED

A Groundbreaking Stand-Alone Diagnostic Kit to Predict Human Papilloma Virus Infections Evolving into Cervical Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HPV OncoPredict project word cloud

Explore the words cloud of the HPV OncoPredict project. It provides you a very rough idea of what is the project "HPV OncoPredict" about.

strategies    315    huge    250    risk    recommended    identification    cytology    starting    smears    smear    hiantis    feared    preventable    innovative    tests    cellular    positive    kills    subsequent    guidelines    competitor    disease    samples    earlier    diagnostic    accurate    viral    frequently    clinician    hpv    causing    despite    patented    persistent    technologies    detection    primary    population    genefirst    ivd    manner    infection    responsible    benefit    cancer    oncopredict    nucleic    shape    detecting    healthcare    replace    stand    formed    overwhelming    infected    pap    triage    leaders    women    feed    cc    biomarkers    10    prevention    disruptive    cervical    companies    capacity    patient    alone    device    treatment    acids    collected    opinion    people    undergo    performed    diagnosis    hrhpv    market    ahead    vaccination    genotypes    papillomavirus    reliably    self    patients    million    screening    curable    human    annually    young    stratify    oncogenic    detected    single    truly   

Project "HPV OncoPredict" data sheet

The following table provides information about the project.

Coordinator		 GENEFIRST LIMITED 

Organization address
address: BUILDING E5 CULHAM SCIENCE CENTRE
city: ABINGDON
postcode: OX14 3DB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website https://www.genefirst.com/hpv-oncopredict
 Total cost 2˙945˙000 €
 EC max contribution 2˙923˙061 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENEFIRST LIMITED UK (ABINGDON) coordinator 1˙700˙000.00
2    HIANTIS SRL IT (MILAN) participant 1˙223˙061.00

Map

 Project objective

Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment.

HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders.

The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.

 Publications

year authors and title journal last update
List of publications.
2018 M. Arbyn, E. Peeters, I. Benoy, D. Vanden Broeck, J. Bogers, P. De Sutter, G. Donders, W. Tjalma, S. Weyers, K. Cuschieri, M. Poljak, J. Bonde, C. Cocuzza, F.H. Zhao, S. Van Keer, A. Vorsters
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
published pages: 52-56, ISSN: 1386-6532, DOI: 10.1016/j.jcv.2018.08.006 		Journal of Clinical Virology 107 2019-11-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HPV ONCOPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HPV ONCOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More